A look back at 2021 and a vision for 2022

As we enter a new year, iSTAR Medical’s CEO Michel Vanbrabant reflects on 2021 and the progress iSTAR Medical has made in the development of its innovative minimally invasive implant, MINIjectTM, for people affected by glaucoma.

iSTAR Medical shows initial positive progress of US STAR-V trial for MINIject

Pivotal trial of MINIject, STAR-V, now initiated in 13 sites across the US Positive feedback from world-leading glaucoma surgeons involved in the trial MINIject is the only commercially available MIGS device targeting the supraciliary space. Commercial rollout continues following European approval in 2021 WAVRE, Belgium — 12 January 2022: iSTAR Medical, a medtech company delivering […]

Belgian med-tech innovator iSTAR Medical secures €20 million European financing from the EIB

The EIB has signed a €20 million quasi-equity agreement with Belgian-based medical technology company iSTAR Medical SA iSTAR Medical’s innovative device MINIject® is expected to set new standards in terms of ophthalmic implants for patients suffering glaucoma, the leading cause of irreversible blindness in the world. iSTAR Medical will use the funding to accelerate its […]

iSTAR Medical receives European market approval for glaucoma implant MINIject

The only commercially available, minimally invasive supraciliary device for glaucoma now approved First commercial implantations of MINIject successfully carried out by world-leading ophthalmologist Prof. Dr. Burkhard Dick at the University Eye Hospital Bochum, Germany European launch represents pivotal milestone in iSTAR Medical’s commercial strategy to bring MINIject to patients globally WAVRE, Belgium — 17 November […]

iSTAR Medical present final results from STAR-II European trial for MINIject in glaucoma patients at AAO

Data from STAR-II trial show consistently outstanding performance and safety in patients with primary open-angle glaucoma up to two-years post implantation